CSIMarket Company Name, Ticker, Customers, else..
 
Rayzebio Inc   (NASDAQ: RYZB)
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 15
 Employees 52
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 377
 Cash Flow (TTM) (Millions $) 123
 Capital Exp. (TTM) (Millions $) 32

Business Description


Rayzebio Inc is a biotechnology company that focuses on the development and commercialization of innovative therapies for various diseases, particularly in the field of oncology. The company utilizes advanced molecular imaging technologies and biomarker analysis to identify specific targets for treatment. Rayzebio is dedicated to improving patient outcomes and has a strong pipeline of potential therapies under development. They collaborate with academic institutions and other industry partners to conduct research and clinical trials, ensuring the validity and effectiveness of their products. Overall, Rayzebio is committed to revolutionizing the approach to disease treatment and providing hope to patients and their families.


   Company Address: 5505 Morehouse Drive, San Diego 92121 CA
   Company Phone Number: 937-2757   Stock Exchange / Ticker: NASDAQ RYZB


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -2.13%    
EBS   -3.56%    
ICPT        0.21% 
OPK        1.23% 
REGN        0.83% 
SUPN        0.86% 
• View Complete Report
   



Business Update

Bristol Myers Squibb Expands Portfolio with RayzeBio Acquisition, Gaining Ground in Radiopharmaceutical Therapeutics

Published Mon, Feb 26 2024 1:35 PM UTC

In a recent announcement, Bristol Myers Squibb (BMS) proudly declared the successful finalization of its acquisition of RayzeBio, Inc., a prominent player in the field of radiopharmaceutical therapeutics (RPTs). With the completion of this merger, RayzeBio has become a fully owned subsidiary of BMS, marking a significant step forward for both companies. Let us delve into the...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 34.09
Working Capital Ratio 34.39
Leverage Ratio (MRQ) 0.03
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -7.81 $
Revenues (TTM) -
Cash Flow (TTM) 7.97 $
Cash 35.08 $
Book Value 37.36 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) 7,242,692
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) 164.76 %
Return On Investment (TTM) 117.64 %
Return On Equity (TTM) 324.65 %
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.